Furthermore, preclinical studies in several murine tumor models, including lung carcinoma, have demonstrated that depletion of CCR8+ Tregs by anti-CCR8 antibody administration resulted in a marked anti-tumor effect [16–22]. Here, CCR8 is linked to neoplasm.